These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12933586)

  • 21. The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally.
    Kassim AA; DeBaun MR
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):532-541. PubMed ID: 38066894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
    Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease.
    Altrock PM; Brendel C; Renella R; Orkin SH; Williams DA; Michor F
    Am J Hematol; 2016 Sep; 91(9):931-7. PubMed ID: 27299299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-level allogeneic chimerism achieved by prenatal tolerance induction and postnatal nonmyeloablative bone marrow transplantation.
    Peranteau WH; Hayashi S; Hsieh M; Shaaban AF; Flake AW
    Blood; 2002 Sep; 100(6):2225-34. PubMed ID: 12200389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An irradiation-free nonmyeloablative bone marrow transplantation model: importance of the balance between donor T-cell number and the intensity of conditioning.
    Kuwatani M; Ikarashi Y; Mineishi S; Asaka M; Wakasugi H
    Transplantation; 2005 Nov; 80(9):1145-52. PubMed ID: 16314778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
    Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
    Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.
    Kim YM; Mapara MY; Down JD; Johnson KW; Boisgerault F; Akiyama Y; Benichou G; Pelot M; Zhao G; Sykes M
    Blood; 2004 Jan; 103(2):732-9. PubMed ID: 14512313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Robust tolerance to fully allogeneic islet transplants achieved by chimerism with minimal conditioning.
    Luo B; Nanji SA; Schur CD; Pawlick RL; Anderson CC; Shapiro AM
    Transplantation; 2005 Aug; 80(3):370-7. PubMed ID: 16082333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
    Ploemacher RE; Johnson KW; Rombouts EJ; Etienne K; Westerhof GR; Baumgart J; White-Scharf ME; Down JD
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):236-45. PubMed ID: 15077222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.
    Fitzhugh CD; Cordes S; Taylor T; Coles W; Roskom K; Link M; Hsieh MM; Tisdale JF
    Blood; 2017 Oct; 130(17):1946-1948. PubMed ID: 28887325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease.
    Abraham A; Hsieh M; Eapen M; Fitzhugh C; Carreras J; Keesler D; Guilcher G; Kamani N; Walters MC; Boelens JJ; Tisdale J; Shenoy S; ;
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2178-2183. PubMed ID: 28882446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance.
    Hu M; Kramer B; Zhang GY; Wang YM; Watson D; Howden B; McCowage G; Alexander IE; Gunning P; Alexander SI
    Transplantation; 2015 Dec; 99(12):2476-84. PubMed ID: 26177088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor.
    McPherson ME; Anderson AR; Haight AE; Jessup P; Castillejo MI; Hillyer CD; Josephson CD
    Transfusion; 2009 Sep; 49(9):1977-86. PubMed ID: 19453984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Busulfan as a myelosuppressive agent for generating stable high-level bone marrow chimerism in mice.
    Peake K; Manning J; Lewis CA; Barr C; Rossi F; Krieger C
    J Vis Exp; 2015 Apr; (98):e52553. PubMed ID: 25867947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for ineffective erythropoiesis in severe sickle cell disease.
    Wu CJ; Krishnamurti L; Kutok JL; Biernacki M; Rogers S; Zhang W; Antin JH; Ritz J
    Blood; 2005 Nov; 106(10):3639-45. PubMed ID: 16091448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
    Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
    Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: A review of current and future methods.
    Lewis J; Greenway SC; Khan F; Singh G; Bhatia M; Guilcher GMT
    Am J Hematol; 2022 Oct; 97(10):1359-1371. PubMed ID: 35583381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimen.
    Bradley MB; Sattler RM; Raftopoulos H; Ward M; Grossman IR; Townes TM; Ryan TA; Bank A
    Biol Blood Marrow Transplant; 2002; 8(8):453-61. PubMed ID: 12234171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.